drugset
drugset / Trial / NCT06689540

Mts105 for Advanced Hepatocellular Carcinoma

NCT06689540 ↗

Phase 1 Recruiting 14 enrolled Shen Lin METiS Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.

Timeline

Start
2024-11-18
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MTS105 Messenger RNA (mRNA) 0.05 ug/kg Intravenous
Subject MTS105 Messenger RNA (mRNA) 0.5 ug/kg Intravenous
Subject MTS105 Messenger RNA (mRNA) 3 ug/kg Intravenous
Subject MTS105 Messenger RNA (mRNA) 15 ug/kg Intravenous
Subject MTS105 Messenger RNA (mRNA) 30 ug/kg Intravenous
Subject MTS105 Messenger RNA (mRNA) 45 ug/kg Intravenous

Indications

hepatocellular carcinoma